Ignite Creation Date:
2025-12-24 @ 2:53 PM
Ignite Modification Date:
2026-01-14 @ 9:11 AM
Study NCT ID:
NCT03402659
Status:
COMPLETED
Last Update Posted:
2021-10-27
First Post:
2018-01-11
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
Sponsor:
EIP Pharma Inc
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
EIP-VX17-745-304
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None